FCN1: A Protein Involved in Neurological and Psychiatric Disorders and Potential Drug Targets

Target Name: FCN1

NCBI ID: G2219

FCN1

FCN1: A Protein Involved in Neurological and Psychiatric Disorders and Potential Drug Targets

FCN1 (Focal Constriction Nuclei 1), also known as FCN1_HUMAN, is a protein that is expressed in the human brain and is known for its role in the formation and maintenance of blood vessels in the brain. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells and tissues.

FCN1 has been shown to play a critical role in the development and progression of a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It is also involved in the regulation of pain and inflammation, and has been shown to play a role in the development of cancer.

In addition to its role in neurological and psychiatric disorders, FCN1 is also a potential drug target. Researchers have identified several potential small molecules that can interact with FCN1 and have shown that these molecules have the potential to treat a number of neurological and psychiatric disorders.

One of the most promising small molecules that has been shown to interact with FCN1 is called N-Acetyl-L-Tyrosine (N-ATYR), which is a neurotransmitter that is involved in the regulation of mood, anxiety, and pain. N-ATYR has been shown to interact with FCN1 and can inhibit the activity of FCN1 in a number of ways.

Another small molecule that has been shown to interact with FCN1 is called 2-Mercaptoethanesulfonic acid (2-MES), which is a compound that has been shown to have anti-inflammatory and neuroprotective effects. 2-MES has been shown to interact with FCN1 and can inhibit the activity of FCN1 in a number of ways.

In addition to N-ATYR and 2-MES, a number of other small molecules have also been shown to interact with FCN1 and have the potential to treat neurological and psychiatric disorders. These molecules include drugs that are currently being used to treat depression, anxiety, and other psychiatric disorders, as well as compounds that have been shown to have potential anti-inflammatory and neuroprotective effects.

While FCN1 is an interesting protein that has been shown to play a critical role in the development and progression of a number of neurological and psychiatric disorders, it is also a potential drug target. Further research is needed to fully understand the role of FCN1 in the regulation of neurological and psychiatric disorders, as well as the potential utility of small molecules that interact with FCN1 as drug treatments.

Protein Name: Ficolin 1

Functions: Extracellular lectin functioning as a pattern-recognition receptor in innate immunity. Binds the sugar moieties of pathogen-associated molecular patterns (PAMPs) displayed on microbes and activates the lectin pathway of the complement system. May also activate monocytes through a G protein-coupled receptor, FFAR2, inducing the secretion of interleukin-8/IL-8 (PubMed:21037097). Binds preferentially to 9-O-acetylated 2-6-linked sialic acid derivatives and to various glycans containing sialic acid engaged in a 2-3 linkage

The "FCN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets